Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Development of a universally effective influenza virus

Sep. 3, 2018

Initial single-dose data presented from phase I study of NasoShield

Sep. 3, 2018

Cynata stem cell therapy meets safety and efficacy endpoints in phase I trial in GvHD

Aug. 31, 2018

Viela Bio initiates first-in-human study of VIB-9600

Aug. 22, 2018

Target of rapamycin complex 1 inhibition improves immune function in elderly subjects

Aug. 20, 2018

Mustang Bio, St. Jude's Children's Research Hospital to develop gene therapy for X-SCID

Aug. 14, 2018

Petrovax Pharm's 4-valeant influenza vaccine --Grippol Quadrivalent-- approved in Russia

Aug. 10, 2018

Positive data announced from phase II extension study of MVA-BN RSV universal vaccine

Aug. 9, 2018

Immunose FLU nasal influenza vaccine candidate demonstrates good safety in older adults

Aug. 9, 2018

First participant enrolled in phase III study of M-001 universal flu vaccine candidate

Aug. 9, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...